Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Accumulated Expenses (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Accumulated Expenses data on record, last reported at $735238.0 in Q3 2025.

  • For Q3 2025, Accumulated Expenses fell 52.14% year-over-year to $735238.0; the TTM value through Sep 2025 reached $735238.0, down 52.14%, while the annual FY2024 figure was $344138.0, 52.63% down from the prior year.
  • Accumulated Expenses reached $735238.0 in Q3 2025 per GANX's latest filing, up from $547270.0 in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $2.1 million in Q3 2022 and bottomed at $325079.0 in Q2 2021.
  • Average Accumulated Expenses over 5 years is $1.0 million, with a median of $1.1 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: surged 229.27% in 2022, then plummeted 62.49% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $681770.0 in 2021, then surged by 58.72% to $1.1 million in 2022, then crashed by 32.86% to $726474.0 in 2023, then tumbled by 52.63% to $344138.0 in 2024, then surged by 113.65% to $735238.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $735238.0 in Q3 2025, $547270.0 in Q2 2025, and $413488.0 in Q1 2025.